Hepatology on the AMU
|
|
|
- Rolf Moore
- 5 years ago
- Views:
Transcription
1 Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge
2 Is liver disease relevant to me? Williams R, Lancet 2014
3 Is liver disease relevant to me? Leon DA, Lancet 2006
4 Is liver disease relevant to me? Number (prop) At risk of liver disease 12,000,000 (1/5) Basis of estimate With significant liver disease 600,000 (1/100) Estimated from end-stage figures/natural history With cirrhosis 60,000 (1/1000) Estimated from sources/natural history Have primary liver cancer Have liver disease as direct cause of death 3000/yr(1/20,000) Undergo liver transplantation 800 (1/70,000) 12,000 (1/5,000) Contributoryin 36,000 deaths/anum Liver Disease: The NHS Atlas of Variation in Healthcare for People with Liver Disease
5
6
7
8
9 I want us to be up there with the best in Europe when it comes to tackling the leading causes of early death, starting with the five big killer diseases cancer, heart, stroke, respiratory and liver disease.
10 NCEPOD review (2013) Consultant Hepatologistspresent in only 28% of hospitals ( with an interest in 73% DGHs and 81% teaching hospitals) 1/3 of patients who were thought to have required escalation of care did not receive it due to reluctance to escalate in ARLD A decision to limit care/withdraw treatment was inappropriate in 17% In more thant 1/2 overall care was rated as having room for improvement /poor
11
12 The postcode lottery Williams R, Lancet 2014
13 The postcode lottery Social deprivation late presentation and comorbidity Education of primary care late diagnosis Imbalance in transplant centres - education and access to e.g. TIPSS/transfer Williams R, Lancet 2014
14 The postcode lottery Social deprivation late presentation and comorbidity Education of primary care late diagnosis Imbalance in transplant centres - education and access to e.g. TIPSS/transfer Williams R, Lancet 2014
15 Aims What is acute on chronic liver disease? Pathophysiology Specific aspects to get you through the weekend! circulatory and renal dysfunction, nutrition Who to escalate to ITU? Role of transplant
16 What is acute on chronic liver disease?
17 Spectrum of chronic liver disease STEATOSIS e.g. alcoholic liver disease, nonalcoholic fatty liver disease HEPATOCELLULAR CARCINOMA INFLAMMATION e.g. viral, autoimmune, alcohol, wilson s, drugs FIBROSIS CIRRHOSIS MALNUTRITION IRON OVERLOAD e.g. hereditoryhaemochromatosis, secondary iron overload NON-CIRRHOTIC: Pre-hepatic e.g. portal vein thrombosis Intra-hepatic e.g noncirrhotic portal hypertension, schistosomiasis Post-hepatic e.g. Buddchiarisyndrome, cardiac failure PORTAL HYPERTENSION VARICES ASCITES RENAL DYSFUNCTION ENCEPHALOPATHY ASYMPTOMATIC SYMPTOMATIC
18 What is acute on chronic liver disease? Characteristicsof patientsadmitted with acute decompensation (n=1343) Mean age (yrs) 57.2 Male sex (%) 64 Aetiology of cirrhosis (%): Alcohol Hepatitis C Alcohol plus hepatitis C Any previous hospitalisation (%) 47 Cause of current hospitalisation (%) Ascites Encephalopathy GI haemorrhage Bacterial infection Moreau R (CANIONIC study), Gastroenterology 2013
19 What is acute on chronic liver disease? Decompensated cirrhosis = hepatic and other organ dysfunction occurring in the context of gradual progression of cirrhosis over months. Bernal W, Lancet 2015
20 What is acute on chronic liver disease? Decompensated cirrhosis = hepatic and other organ dysfunction occurring in the context of gradual progression of cirrhosis over months. Acute on chronic liver failure = Short-term deterioration in hepatic and other organ function in a patient with chronic liver disease over days to several weeks after a defined or undefined precipitating illness Bernal W, Lancet 2015
21 Jalan R, J Hepatology 2012
22
23 Acute alcoholic hepatitis Typically will have stopped drinking 1-2 weeks before presentation Severe hepatic inflammation often leading to SIRS and multiorgan dysfunction Hotchkiss RS, Nat Med 2009
24 Acute alcoholic hepatitis Typically will have stopped drinking 1-2 weeks before presentation Severe hepatic inflammation often leading to SIRS and multiorgan dysfunction Labs PT Increased Bilirubin ALT ~ Alk phos ~ Albumin Low WCC O en CRP <50 Forrest E, Gut 2005
25 Pathophysiology
26 The baseline multiorgan dysfunction
27 Portal hypertension Splanchnic vasodilatation with reduced effective circulating volume Leithead/Hayes/Ferguson, AP&T 2014
28 Portal hypertension Splanchnic vasodilatation with reduced effective circulating volume Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
29 Portal hypertension Splanchnic vasodilatation with reduced effective circulating volume Increased cardiac output Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
30 Portal hypertension Splanchnic vasodilatation with reduced effective circulating volume Increased cardiac output Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
31 Portal hypertension Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
32 Portal hypertension Bacterial translocation with low grade SIRS Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
33 Portal hypertension Bacterial translocation with low grade SIRS Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
34 Portal hypertension Bacterial translocation with low grade SIRS Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
35 DIURETICS LVP Portal hypertension Bacterial translocation with low grade SIRS? Hepato-renal reflex Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
36 DIURETICS LVP INFECTION HAEMORRHAGE Portal hypertension Bacterial translocation with low grade SIRS? Hepato-renal reflex Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
37 DIURETICS LVP INFECTION HAEMORRHAGE SIRS? Hepato-renal reflex Portal hypertension Bacterial translocation with low grade SIRS Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
38 Portal hypertension Bacterial translocation with low grade SIRS? Hepato-renal reflex Splanchnic vasodilatation with reduced effective circulating volume Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
39 The baseline multiorgan dysfunction Portal hypertension Bacterial translocation with low grade SIRS SPLANCHNIC VASODILATATION WITH REDUCED EFFECTIVE CIRCULATING VOLUME Cardiac dysfunction Increased SNS, RAAS, vaspressin Leithead/Hayes/Ferguson, AP&T 2014
40 Portal hypertension related renal dysfunction Diuretic controlled ascites Hyponatraemia Refractory ascites Hepatorenal syndrome Leithead/Hayes/Ferguson, AP&T 2014
41 Specific aspects to get you through the weekend
42 The basics Treat the cause low threshold for antibiotics, consider invasive fungal infection Prevent circulatory and renal dysfunction Rifaximin, lactulose, enemas Stop NSAIDS, ACE inhibtors, other nephrotoxics; avoid sedating medication Nutrition
43 Managing the circulatory and renal dysfunction
44 Managing the circulatory and renal dysfunction TOP TIPS Ascites is your marker of renal dysfunction Creatinine is falsely low Aim is to increase the effective circulating volume to reduce endogenous vasoactive mediators.
45 Managing the circulatory and renal dysfunction Vasoconstrictors - Terlipressin Reverses type 1 HRS and on meta-analysis results in a small reduction in short-term mortality. But 13% 6-month transplant free survival. Noradrenaline as effective Intravenous human albumin Volume loads plus increases oncotic pressure, binds endotoxin, and has antiinflammatory and antioxidant effect; may impact on endothelial and cardiac dysfunction. Garcia-Martinez et al, Hepatology 2013 Fernandez et al, J Hepatol 2005 Fernandez et al, Hepatology 2005 Ortega et al, Hepatology 2002 Gluud et al, Cochrane Database Syst Rev 2012 Sanyal et al, Gastroenterology 2008 Salerno et al, Gut 2007 Alessandria et al, J Hepatol 2007 Sharma et al, Am J Gastroenterol 2008 Singh et al, J Hepatol2012
46
47 Managing the circulatory and renal dysfunction Vasoconstrictors - Terlipressin Reverses type 1 HRS and on meta-analysis results in a small reduction in short-term mortality. But 13% 6-month transplant free survival. Noradrenaline as effective Intravenous human albumin Volume loads plus increases oncotic pressure, binds endotoxin, and has antiinflammatory and antioxidant effect; may impact on endothelial and cardiac dysfunction. Garcia-Martinez et al, Hepatology 2013 Fernandez et al, J Hepatol 2005 Fernandez et al, Hepatology 2005 Ortega et al, Hepatology 2002 Gluud et al, Cochrane Database Syst Rev 2012 Sanyal et al, Gastroenterology 2008 Salerno et al, Gut 2007 Alessandria et al, J Hepatol 2007 Sharma et al, Am J Gastroenterol 2008 Singh et al, J Hepatol2012
48 Managing the circulatory and renal dysfunction Vasoconstrictors - Terlipressin Reverses type 1 HRS and on meta-analysis results in a small reduction in short-term mortality. But 13% 6-month transplant free survival. Noradrenaline as effective Intravenous human albumin Volume loads plus increases oncotic pressure, binds endotoxin, and has antiinflammatory and antioxidant effect; may impact on endothelial and cardiac dysfunction. In HRS, results in a 3x increased rate of reversal of renal dysfunction compared to terlipressin alone. Garcia-Martinez et al, Hepatology 2013 Fernandez et al, J Hepatol 2005 Fernandez et al, Hepatology 2005 Ortega et al, Hepatology 2002 Gluud et al, Cochrane Database Syst Rev 2012 Sanyal et al, Gastroenterology 2008 Salerno et al, Gut 2007 Alessandria et al, J Hepatol 2007 Sharma et al, Am J Gastroenterol 2008 Singh et al, J Hepatol2012
49 Managing the circulatory and renal dysfunction Key points re fluid filling The fluid is in the wrong place Leaky pulmonary circulation CVP not helpful Avoid 5% dextrose (<5% remains intravascular) 500ml 5% = 100 mls20% = 20g albumin 40-60g albumin/24 hours (serum albumin does not dictate amount to give)
50 Managing the circulatory and renal dysfunction Key points re ascites Only drain if causing problems ventilating/patient distress (but all patients should have a diagnostic tap) Renal dysfunction is not a contraindication to large volume paracentesis 20g albumin for every 2-3L drained Remove drain within 6-12 hours
51 Paracentesis Umgelteret al, CritCare 2008
52 Paracentesis Umgelteret al, CritCare 2008
53 Paracentesis Umgelteret al, CritCare 2008
54 Nutrition
55 Nutrition Malnutrition and sarcopenia The norm in advanced liver disease including overweight patients Multi-factorial Catabolic state Anorexia (jaundice, ascites) Malabsorption of fat and fat-soluble vitamins Protein loss (ascites, protein loosing enteropathy, nephrotic syndrome) Nutrition intricately linked with immune function therefore increased risk of infection. Increasingly recognised as a poor prognostic indicator
56 Nutrition Cirrhotic eating pattern: carbohydrate consumption every 2-3 hours (little and often eating pattern) and 50g bedtime carbohydrate snack prevents gluconeogenesis High protein intake recommended ( g/kg) Do not protein restrict no evidence this improves HE and may actually worsen it by causing muscle catabolism. Muscle plays important role in ammonia removal in liver disease High energy, high protein low volume oral nutritional supplement drinks useful Low threshold for enteral nutrition support if oral intake not meeting requirements Dietitianreferral for monitoring of nutritional status (MUAC, MAMC, HGS) and specialist advice If at risk of refeedingsyndrome: refeedingvitamins, gradual introduction of nutrition (but not too slow) and monitor K, Mg, PO4 and AdjCa
57 What s needed to meet requirements? 70kg Man: 2600kcal, g protein/day Breakfast Supper Snacks 400kcal 12.5g protein Lunch 370kcal 14g protein Total 2645kcal Bedtime 96.5g 310kcal 13g protein Supplements 680kcal 25g protein 285kcal 8g protein 600kcal 24g protein
58 Who to escalate to ITU?
59
60 Birmingham liver transplant waiting list survival
61 Jalan R, J Hepatology 2012
62 Bernal W, Lancet 2015
63 Bernal W, Lancet 2015
64 Cholangitas, AP&T 2006
65 GinesP, J Hepatol2012
66 CLIF-SOFA score Organ failure Liver Bilirubin>200 Kidney Creatinine>177 Cerebral Encephalopathy grade III/IV Coag INR 2.5/platelets<20 Circ Any vasopressor (incl terli) Lungs Pa02/Fi Moreau R, J Hepatology 2012
67 Mechanical ventilation (45%) 26 Vasopressors (41%) 19 RRT (10%) % survival Severe infection 36 Type 1 HRS 58 Hepatic encephalopathy 74 Variceal haemorrhage % survival Levesque E, J Hepatology 2012
68 Das V, CritCare Med 2010
69 Role of transplantation.
70 Role of transplantation.
71 Final comments Patients frequently present late and prognosis may be short Often socially isolated/vulnerable End of life care
72 Questions
The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
Hepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
Initial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
King s College Hospital NHS Foundation Trust. Acute on Chronic Liver Failure: Practical management outside the tertiary centre.
King s College Hospital NHS Foundation Trust NHS Acute on Chronic Liver Failure: Practical management outside the tertiary centre. William Bernal Professor of Liver Critical Care Liver Intensive Therapy
Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
Management of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
Management of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
CONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:
Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:
Developed for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 28 May 2018 Reviewed 1 June 2018 To be reviewed 1 June 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use 1 National
Complications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
Liver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS.
ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS. Vicente Arroyo 1, 2, Rajiv Jalan 2, 3 1 Institut de Investigacions Biomèdiques August Pi I Sunyer. University of Barcelona.
Hepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
PACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
Infections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
Hepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
PACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
GI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
Nutrition Management of End- Stage Liver Failure
Nutrition Management of End- Stage Liver Failure Krystel Ouaijan, RDN, MSc Nutrition Support Dietitian in Saint George Hospital UMC PhD in University of Geneva Just few questions https://www.mentimeter.com/s/c1c1be18dc2
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis
The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis http://www.funnyjunk.com/funny_pictures/1743659/enlarged/ Daniel Giddings,
Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
Developed for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 10 December 2010 Reviewed 1 June 2012 To be reviewed 1 June 2014 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use
Causes of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
Beta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
LIVER DISORDERS (PRACTICAL MANAGEMENT) Dr Pok Kern (PK) TAN Gastroenterologist Calvary hospital, ACT 1 st April 2017
LIVER DISORDERS (PRACTICAL MANAGEMENT) Dr Pok Kern (PK) TAN Gastroenterologist Calvary hospital, ACT 1 st April 2017 TOPICS TO COVER Acute liver failure Chronic liver failure Portal hypertension : Ascites
CHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
Sign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
End-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis
168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department
REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
Hepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
BETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
Elevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
CHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
Hepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
Liver-Kidney Crosstalk in Liver and Kidney Diseases
Liver-Kidney Crosstalk in Liver and Kidney Diseases Sundararaman Swaminathan MD Associate Professor Division of Nephrology University of Virginia Health System Charlottesville, VA Hepatonephrologist busily
Chronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
Terlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
Alcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD
Alcoholic Hepatitis: Routine Screening for Early Recognition and Management Juan Guerrero, MD Global Problem 1% of GNP of medium/high income countries Additional societal costs Disproportionately affects
L USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO
AISF-SIMTI POSITION PAPER - L USO APPROPRIATO DELL ALBUMINA Roma, 29 marzo 2016 L USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO Mauro Bernardi Semeiotica Medica Dipartimento di Scienze Mediche
Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications
PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications Edy G. Trujillo, RN, MSN, ACNP-BC Liver Transplant RRUCLA Medical Center July 31, 2018 What Do We All Look Forward
Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015
Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015 Protein-calorie malnutrition (PCM) is extremely common
NUTRITIONAL OPTIMIZATION IN PRE LIVER TRANSPLANT PATIENTS
NUTRITIONAL OPTIMIZATION IN PRE LIVER TRANSPLANT PATIENTS ACHIEVING NUTRITIONAL ADEQUACY Dr N MURUGAN Consultant Hepatologist Apollo Hospitals Chennai NUTRITION IN LIVER FAILURE extent of problem and consequences
Nutrition in Liver Disease An overview of the EASL Clinical Practice Guidelines
Nutrition in Liver Disease An overview of the EASL Clinical Practice Guidelines Marike Bauermeister Registered Dietitian Wits Donald Gordon Medical Centre Malnutrition Malnutrition is a complication in
Definition: fibrosis and nodular regeneration resulting from hepatocellular injury
Cirrhosis Understanding the liver: Patterns of LFT Abnormalities - Hepatocellular/Transaminitis: o Ratio of AST: ALT >2:1 ETOH (keep in mind AST is also produced by red cells, heart muscle) o If Aminotransferases
Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
Life After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease
NCEPOD - Measuring the Units; A review of patients who died with alcohol-related liver disease Hospital Number Admission to hospital 5. Trusts should ensure that medical patients are reviewed by a consultant
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
Liver Failure. The most severe clinical consequence of liver disease is liver failure:
Liver diseases I The major primary diseases of the liver are: - Viral hepatitis, - Nonalcoholic fatty liver disease (NAFLD), - Alcoholic liver disease, - Hepatocellular carcinoma (HCC) Hepatic damage also
Transplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
ACUTE ON CHRONIC LIVER FAILURE : FROM A TO CLF
ACUTE ON CHRONIC LIVER FAILURE : FROM A TO CLF Wim Laleman, MD, PhD Department of Liver and Biliopancreatic disorders University Hospitals Gasthuisberg, Leuven, BELGIUM wim.laleman@uzleuven.be EVOLVING
ALCOHOLIC LIVER DISEASE (ALD) Nayan Patel, DO Transplant Hepatology/GI Banner Advanced Liver Disease and Transplant Center
ALCOHOLIC LIVER DISEASE (ALD) Nayan Patel, DO Transplant Hepatology/GI Banner Advanced Liver Disease and Transplant Center Objectives Spectrum of alcoholic liver disease Focus on Alcoholic Hepatitis (AH)
Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
Managing Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
PALLIATIVE CARE IN END-STAGE LIVER DISEASE
PALLIATIVE CARE IN END-STAGE LIVER DISEASE Ken S. Ota, DO Family Medicine Banner Good Samaritan Medical Center Learning Objectives: Describe the common bio-psycho-social issues in end-stage liver disease
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
Clinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
Decompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
Prof. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:
Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation
This survey aims to look at individual practice and can be completed by any healthcare professional.
This survey aims to look at individual practice and can be completed by any healthcare professional. If you have any questions about how this form should be completed please contact Dr Grace Ting (ghlting@doctors.net.uk)
Ricky Bell Renal/ICM Registrar
Ricky Bell Renal/ICM Registrar Objectives When to call renal How to manage the patient with AKI How the manage the patient with CKD (HD/PD) Special AKI situations What do the guidelines say? My referral
2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
CIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
Update in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
Evidence Analysis Library Research Project
Evidence Analysis Library Research Project EAL question: What is the evidence to support the use of supplementing BCAA in patients with cirrhosis to 1) prevent further liver damage or improve liver function;
APPROPRIATE PATIENT SELECTION AS A KEY TO INCREASE THE BENEFIT/RISK RATIO FOR ELAD
APPROPRIATE PATIENT SELECTION AS A KEY TO INCREASE THE BENEFIT/RISK RATIO FOR ELAD Ram Subramanian M.D. Hepatology and Critical Care Emory University School of Medicine Atlanta, USA OUTLINE Review the
Hepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital
Hepatology cases for the generalist Will Gelson Consultant Hepatologist Addenbrooke s Hospital 30 y o man with upper GI haemorrhage Background heavy alcohol use Hxof 3 pint haematemesis P 100, BP 90/40,
Healthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The